Compass Therapeutics, Inc.
CMPX
$1.97
$0.105.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -100.00% | -- |
| SG&A Expenses | 12.34% | 11.50% | 10.49% | 19.21% | 35.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.94% | 26.73% | 26.87% | 21.19% | 17.31% |
| Operating Income | -21.59% | -28.63% | -28.81% | -23.05% | -15.72% |
| Income Before Tax | -23.45% | -34.66% | -37.79% | -31.30% | -21.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.45% | -34.66% | -37.79% | -31.30% | -21.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.45% | -34.66% | -37.79% | -31.30% | -21.52% |
| EBIT | -21.59% | -28.63% | -28.81% | -23.05% | -15.72% |
| EBITDA | -22.49% | -29.49% | -29.52% | -23.52% | -16.07% |
| EPS Basic | -2.52% | -20.38% | -27.32% | -24.32% | -12.72% |
| Normalized Basic EPS | -2.47% | -20.34% | -27.31% | -24.28% | -12.71% |
| EPS Diluted | -2.52% | -20.38% | -27.32% | -24.32% | -12.72% |
| Normalized Diluted EPS | -2.47% | -20.34% | -27.31% | -24.28% | -12.71% |
| Average Basic Shares Outstanding | 23.32% | 14.90% | 9.03% | 5.19% | 7.28% |
| Average Diluted Shares Outstanding | 23.32% | 14.90% | 9.03% | 5.19% | 7.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |